DDInter40 DDInter1652
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Alefacept {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bleomycin
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibritumomab tiuxetan
Alefacept {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ibritumomab tiuxetan
Alefacept may lead to a major life threatening interaction when taken with Upadacitinib